Gold prices steady ahead of Fed decision; weekly weakness noted
Cibus, not a seed company but a technology provider, develops and licenses gene-edited traits to seed companies. It focuses on major global row crops like canola, corn, rice, soybean, and wheat, addressing agricultural challenges such as disease and pest management. The company has demonstrated strong revenue growth of 47% over the last twelve months, though InvestingPro analysis indicates significant stock volatility with a beta of 3.16. Cibus's high-throughput gene editing technology streamlines trait development, with several productivity traits in commercial development and advanced trial stages. For deeper insights into Cibus's financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
The warrants, exercisable after stockholder approval, have a five-year lifespan from the date of approval and a $2.50 exercise price. They are redeemable at the company's discretion for $0.0001 per warrant if certain conditions are met, including a successful operational soybean platform announcement and the Class A common stock's closing price reaching at least $5.00 for fifteen consecutive trading days.
Cibus plans to allocate the net proceeds to advance its pipeline of productivity traits and for general corporate needs while seeking long-term financing. A.G.P./Alliance Global Partners (NYSE:GLP) is the sole placement agent for the offering.
The offering also includes amendments to existing Investor Warrants, reducing their exercise price to $2.50 per share and extending their termination date. These changes take effect upon the offering's closure, except for warrants held by CEO Rory Riggs, which require additional stockholder approval.
Cibus, not a seed company but a technology provider, develops and licenses gene-edited traits to seed companies. It focuses on major global row crops like canola, corn, rice, soybean, and wheat, addressing agricultural challenges such as disease and pest management. The company has demonstrated strong revenue growth of 47% over the last twelve months, though InvestingPro analysis indicates significant stock volatility with a beta of 3.16. Cibus's high-throughput gene editing technology streamlines trait development, with several productivity traits in commercial development and advanced trial stages. For deeper insights into Cibus's financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
This offering is pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission. A prospectus supplement detailing the offering terms will be filed with the SEC.
The information in this article is based on a press release statement.
In other recent news, biotechnology firm Cellectis (NASDAQ:CLLS) reported substantial financial and operational updates during its Third Quarter 2024 Earnings Call. The company revealed a significant increase in cash reserves, largely due to a strategic investment from AstraZeneca (NASDAQ:AZN), which boosted the reserves to $264 million, up from $156 million at the end of 2023. This collaboration also spurred the initiation of three new research and development programs, including two allogeneic CAR T therapies and an in vivo gene therapy.
However, Cellectis has decided to deprioritize the UCART123 program to give more attention to these promising new ventures. The company is also focusing on patient enrollment for clinical trials, particularly the BALLI-01 study. The financial management and partnership milestones are expected to extend the company's cash runway to 2027.
Cellectis plans to present Phase I data in 2025 and is committed to maintaining open communication with stakeholders. The collaboration with AstraZeneca has already contributed approximately $34 million in revenues, indicating a positive trajectory for the company's financial health. Despite the deprioritization of the UCART123 program, the firm's strategic focus on its most promising assets and effective financial management has positioned the company for continued progress and a stable financial outlook into 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.